In a study of 432 HER2 positive breast cancers with BM, 37.5% were ER positive HER2 positive and 62.5% were ER negative HER2 positive, and the median overall survival was 16.5 months and 11.5 months, respectively. Here, ERBB2 is linked to breast carcinoma.